Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

18.48 +0.18 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,888,357
Open 18.45
Bid (Size) 18.12 (2)
Ask (Size) 18.73 (2)
Prev. Close 18.30
Today's Range 17.58 - 18.99
52wk Range 11.55 - 18.99
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+8.01%
+8.01%
1 Month
+13.30%
+13.30%
3 Month
+13.93%
+13.93%
6 Month
+35.48%
+35.48%
1 Year
+24.19%
+24.19%

More News

Read More
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
Via Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.